Back to School Report Card: 10 New Health Lessons

Cebranopadol, an investigational oral dual-NMR agonist, satisfied the primary endpoint of statistically significant reduction in pain intensity compared to placebo following abdominoplasty surgery.

In our latest episode, an obesity medicine physician explains the importance of a comprehensive plan to manage chronic pain in patients with obesity.

NX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA.

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

If approved, the nonopioid, centrally acting analgesic would be the first in a new class of medications for fibromyalgia in more than 15 years, Tonix said.

The FDA has set a PDUFA date of January 30, 2025 for the investigational oral nonopioid therapy for acute pain, which could be a first-in-class win for Vertex.